Category: Uncategorized

News from @MedSurgPI and @StarBioPharmaConsulting:  How can early-stage biotechs access senior expertise without blowing the budget? In our latest white paper,  we explore how fractional service providers (FSPs) are helping emerging drug developers streamline operations, reduce costs, and accelerate timelines—without sacrificing quality. From regulatory strategy to real-world evidence, discover how FSPs can drive smarter growth… Read more »

Be FDA-ready from the start. Mesa Science Associates, Inc. and MedSurgPI offer a streamlined Pre-Clinical Checklist to help biotech teams avoid delays and meet FDA expectations. This practical tool covers key areas—CMC, tox, clinical design, regulatory docs, and ops readiness—to ensure your IND plans are complete. Preparing for a Pre-IND or IND? Let’s review your… Read more »

Navigating Early-Stage Biotech Challenges with Practical ExpertiseMedSurgPI is pleased to share this edition of Practical Pointers, offering concise, actionable guidance for biopharmaceutical innovators and Medical Affairs professionals. This issue covers critical considerations in selecting contract manufacturing partners, explores the potential impact of FDA regulatory reform, addresses the responsible use of AI in scientific content generation,… Read more »